Mesothelioma Prognosis - Revision history

MesotheliomaSupport: Add at-a-glance listicle between Overview and Key Facts

2026-03-08T20:56:40Z

Add at-a-glance listicle between Overview and Key Facts

← Older revision		Revision as of 20:56, 8 March 2026
Line 39:		Line 39:

	Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />		Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level [[Mesothelioma_Survival_Statistics\|survival statistics]].<ref name="dandell-diagnosis" /> While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref name="bap1-7fold" /> Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.<ref name="plech" /><ref name="eortc" /> Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.<ref name="dandell-compensation" />

			'''Mesothelioma prognosis at a glance:'''
			* '''Treated patients survive 12–21 months on average''' — but individual outcomes vary dramatically based on stage, histology, age, gender, and molecular markers
			* '''BAP1 mutation carriers survive 7 times longer''' — median 5 years compared to less than 1 year for non-carriers, making genetic testing critical
			* '''Epithelioid subtype doubles survival''' — 14–18 months median versus 4–8 months for sarcomatoid, with 5-year rates of 14% versus 4%
			* '''Women survive nearly 3 times longer''' — 13.4% five-year survival versus 4.5% for men, with 22% reduced mortality risk (HR 0.78)
			* '''Age under 50 means 39% five-year survival''' — compared to just 4.5% for patients 75 and older, a nearly 9-fold difference
			* '''PLECH score (2025) predicts survival most accurately''' — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems
			* '''NLR ≥5 signals 2.7 times higher mortality''' — one-year survival drops from 60% to 26% based on this simple blood test ratio
			* '''Peritoneal patients with complete surgery survive 8.7 years''' — median 104 months after cytoreductive surgery with HIPEC
			* '''High-volume centers reduce surgical death by 31%''' — 10.0% versus 14.6% ninety-day mortality at specialized facilities

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Add Quick Statistics listicle section for GEO; restore Key Facts wikitable

2026-03-08T20:35:07Z

Add Quick Statistics listicle section for GEO; restore Key Facts wikitable

@@ Line 42: / Line 42: @@
 == Key Facts ==
 * '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />
 * '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />
@@ Line 52: / Line 57: @@
 * '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />
 * '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />
 == What Factors Determine Mesothelioma Prognosis? ==
@@ Line 351: / Line 357: @@
 Clinical practice guidelines (2023, European Journal of Human Genetics) recommend genetic counseling and testing for patients with mesothelioma, particularly those diagnosed at younger ages, those with family history of mesothelioma or related cancers (uveal melanoma, renal cell carcinoma), and those with limited or no known asbestos exposure history. BAP1 status has implications for prognosis, treatment planning, and family member surveillance.<ref name="bap1-guidelines" /><ref name="bap1-case" />
 == Get Help ==

MesotheliomaSupport: Fix Key Facts: convert table-wrapped bullets to plain listicle

2026-03-08T20:30:08Z

Fix Key Facts: convert table-wrapped bullets to plain listicle

← Older revision		Revision as of 20:30, 8 March 2026
Line 42:		Line 42:
	== Key Facts ==		== Key Facts ==

	~~{\| class="wikitable" style="width:100%; margin:0; border-collapse:collapse;"~~
	\|-
	~~! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Prognosis~~
	\|-
	~~\| style="padding:15px;" \|~~
	* '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />		* '''Median Overall Survival:''' 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients<ref name="seer-14k" />
	* '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />		* '''BAP1 Mutation Carriers:''' 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers<ref name="bap1-7fold" />
Line 57:		Line 52:
	* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />		* '''Performance Status:''' Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments<ref name="eortc" /><ref name="brims" />
	* '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />		* '''Specialized Centers:''' High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery<ref name="volume-outcomes" />
	\|}

	== What Factors Determine Mesothelioma Prognosis? ==		== What Factors Determine Mesothelioma Prognosis? ==

MesotheliomaSupport: Add comprehensive Mesothelioma Prognosis page with prognostic scoring systems, BAP1 mutations, blood biomarkers, and age-specific survival data

2026-03-08T20:17:19Z

Add comprehensive Mesothelioma Prognosis page with prognostic scoring systems, BAP1 mutations, blood biomarkers, and age-specific survival data

Show changes

MesotheliomaSupport: Create redirect

2026-02-20T01:26:05Z

Create redirect

New page

#REDIRECT [[Mesothelioma Survival Statistics]]